IGC PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
IGC PHARMA, INC. (IGC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-08-14
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.00.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.00.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2024-06-30 was $0.00.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2023-06-30 was $0.00.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2025 was $1.39.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2023 was $1.39, a 208.89% increase from fiscal 2022.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2022 was $0.45, a 15.38% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $0.00 10-KT · filed 2026-03-18 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $1.39 10-K · filed 2025-06-27 | |||
| 2024-12-31 | $0.00 10-Q · filed 2025-02-14 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $0.00 10-K · filed 2024-06-24 | |||
| 2023-12-31 | $0.00 10-Q · filed 2024-02-14 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $1.39 10-K · filed 2023-07-07 | |||
| 2022-12-31 | $0.00 10-Q · filed 2023-02-14 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $0.45 10-K · filed 2022-06-23 | |||
| 2021-12-31 | $1.35 10-Q · filed 2022-02-10 | |||
| 2021-09-30 | $1.35 10-Q · filed 2021-10-29 | |||
| 2021-03-31 | $0.39 10-K · filed 2021-06-14 | |||
| 2020-12-31 | $0.00 10-Q · filed 2021-02-16 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-20 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-19 | |||
| 2020-03-31 | $0.45 10-K · filed 2020-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |